I can comb through more abstracts from ASCO, but why do that when I can have a Certified Lymphoma Rock Star do it for me?
In a Medscape Today video, Dr. Bruce Cheson of Georgetown University Hospital gives a brief summary of all of the important lymphoma-related abstracts from the conference, including the couple that I have reviewed already. (And yes, he and I agree about some of the significance of some of the research).
The video is called "Blood Cancers: Lymphoma, Myeloma Preview," and in it, Dr. Cheson gives his take on some of the abstracts. (The link also includes a written transcript of what he has to say, if you'd rather read than watch.)
Among the abstracts that he addresses are a study comparing R-CHOP and CHOP + Bexxar (the RadioImmunoTherapy treatment). He promises this one will be controversial.
There will also be an update on the RESORT trial, which recently found that Rituxan Maintenance did not offer significant improvement over watching and waiting after initial treatment.
Another I'll be very interested in: an update on the STIL (Study group of Indolent Lymphomas) trial that compared CHOP and Bendamustine, and which in previous years has gone a long way toward Bendamustine elbowing out CHOP as a preferred fontline treatment for indolent lymphomas like Follicular. We'll get updated information on the trial.
Should be very interesting. As we inch closer to the dates of the conference, we'll start to see some press releases from the sponsors of various studies. We'll see then which studies seem most significant, at least in the sponsors' eyes -- those things that are most worth bragging about.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment